Bristol-Myers Squibb (BMY) says it's stopped development of an experimental hepatitis C...
Thursday, August 23, 2012, 7:31 PM ETBristol-Myers Squibb (BMY) says it's stopped development of an experimental hepatitis C treatment connected to the hospitalization of nine patients and the death of one. The drug, known as BMS-986094, had been used in a mid-stage clinical study, which BMY recently suspended. The cause of the adverse events, while not "definitively established," involved heart and kidney toxicity, the drug maker said.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles